Visceral Adipose Tissue (VAT): Sex- and Cycle-Related Differences, Normal Ranges, and Optimal Targets

Visceral adipose tissue (VAT) is the fat stored around the abdominal organs, inside the peritoneal cavity, as distinct from subcutaneous fat stored under the skin. It is most often estimated non-invasively with dual-energy X-ray absorptiometry (DEXA), or measured more precisely with CT or MRI. VAT is not simply "belly fat" as seen on a scale or in a mirror; two people with identical waist size can have very different visceral fat mass.

The useful question for most readers is not "what is the normal VAT number" but "how should the same VAT number be interpreted differently depending on sex, menstrual and menopausal status, and what a reader is actually trying to change." A single universal cutoff applied without that context will overstate risk in some people and understate it in others.

The core answer, with its boundary

Men accumulate visceral fat more readily than premenopausal women at the same total body fat percentage, an effect attributed to estrogen's role in directing fat storage toward subcutaneous gluteal-femoral depots rather than the visceral compartment. This protection is substantially reduced after menopause, when visceral fat tends to rise over the following several years even without weight gain. DEXA-derived VAT area below roughly 100 cm² is commonly treated as a reasonable target in adults, with values above roughly 160 cm² associated with higher cardiometabolic risk in observational research, though these cut-points were derived largely from CT studies and their exact translation to DEXA, and their applicability across ages and both sexes, has not been fully standardized. Menstrual cycle phase causes a measurable but generally small change in total body fat and fluid on DEXA, and is unlikely to move VAT across a clinically meaningful threshold within a single cycle.

What is established, what is plausible, and what is not established

Established (consistent across multiple lines of evidence):

• Visceral fat is metabolically distinct from subcutaneous fat and is more strongly linked to insulin resistance and cardiovascular risk markers.
• Sex differences in fat distribution emerge around puberty and are hormonally mediated: estrogen favors subcutaneous storage, and men without that estrogen exposure accumulate more visceral fat at a given body fat percentage.
• Menopause is associated with a shift toward increased visceral fat, coinciding with the drop in circulating estradiol.
• Weight loss produced by GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) in large randomized trials reduces total fat mass substantially, and imaging substudies have reported disproportionately larger visceral than subcutaneous fat loss.

Plausible but not firmly quantified for a general reader:

• The specific numeric VAT cutoffs (100 cm², 160 cm²) as applied to DEXA rather than CT, and as applied identically across sexes and ages. These figures are widely repeated in the clinical literature and are reasonable planning targets, but readers should treat the exact numbers as approximate rather than diagnostic thresholds.
• The magnitude of VAT-specific reduction from testosterone therapy, GLP-1 agonists, or specific diet patterns. Directionally these interventions reduce VAT; the precise percentages cited in various sources vary by study population and should be verified against the primary trial report before being used to set expectations for an individual.

Not established:

• That any single VAT number carries the same absolute risk for a premenopausal woman, a postmenopausal woman, and a man of the same age. Sex- and stage-specific reference ranges are not yet standardized across DEXA manufacturers.
• That intermittent fasting or time-restricted eating produces VAT-specific reduction beyond what is expected from equivalent weight loss. A 2024 study comparing Ramadan fasting with a traditional intermittent-fasting protocol found distinct effects on markers of body fat storage, but did not establish a VAT-specific advantage independent of caloric intake, and the findings need confirmation before being generalized (Ismail et al. 2024).

How estrogen and testosterone shape where fat is stored

Estradiol acts on estrogen receptor-alpha in adipose tissue and is understood to favor storage of triglycerides in subcutaneous gluteal-femoral fat rather than the visceral compartment. This is the mechanistic basis for the common observation that premenopausal women can have a higher total body fat percentage than men of the same age while still carrying meaningfully less visceral fat.

Testosterone's relationship to VAT in men runs in the opposite direction: lower testosterone is associated with higher visceral fat at a given body weight, and randomized trials of testosterone therapy in men with confirmed hypogonadism have reported reductions in DEXA-measured VAT over 6-12 months. The exact percentage reduction varies by trial and baseline testosterone level, and readers considering testosterone therapy for body composition reasons should discuss trial-specific data with a clinician rather than rely on a single quoted number. Testosterone therapy in men is FDA-approved only for confirmed hypogonadism, not for body composition goals in men with normal testosterone.

Testosterone therapy in women for body composition is off-label in the United States; there is no FDA-approved testosterone product indicated for this use in women, and the supporting trials are smaller and shorter than the male hypogonadism literature. Any decision to use it should weigh unclear long-term safety data against a modest and not yet well-quantified body composition benefit.

Does the menstrual cycle change VAT enough to matter?

Progesterone in the luteal phase increases fluid retention, which affects DEXA-derived total fat mass and lean mass more than it affects the visceral fat estimate specifically. Total fat mass on DEXA can shift by roughly a kilogram or more across the cycle in some studies, largely from fluid, while the visceral fat area itself changes much less. For someone tracking VAT over time, the practical implication is not that the number is meaningless mid-cycle, but that comparing scans taken at different, unmatched cycle phases introduces noise that can be mistaken for a real change.

Practical guidance: for reproductive-age women getting serial DEXA scans, scheduling scans at a consistent cycle phase (many clinics use the early follicular phase, roughly days 2-5) reduces this noise and makes month-to-month or year-to-year comparisons more reliable.

Menopause and hormone therapy

The transition through menopause is associated with an increase in visceral fat that appears to exceed what would be expected from aging alone, coinciding with the fall in circulating estradiol. Randomized trial evidence on menopausal hormone therapy (MHT) and body composition, including data referenced in the Menopause Society's hormone therapy position statement, supports a modest protective or attenuating effect of estrogen-containing therapy on visceral fat gain during this transition, though MHT is prescribed for symptom management and individualized risk-benefit reasons, not as a body composition treatment, and its use should be decided with a clinician weighing cardiovascular, breast, and thromboembolic risk factors specific to the patient. Readers should treat any specific published percentage reduction in VAT with MHT as a research finding requiring context, not a guaranteed individual outcome.

GLP-1 and dual GIP/GLP-1 agonists

Semaglutide (marketed as Wegovy for chronic weight management) and tirzepatide (marketed as Zepbound) are FDA-approved for weight management in adults with obesity or overweight with a weight-related condition, based on large randomized trials showing substantial mean weight loss compared with placebo over roughly 68-72 weeks. Imaging substudies within these trials, using DEXA or MRI, have reported that visceral fat declines proportionally more than subcutaneous fat during treatment. Exact substudy percentages for VAT reduction are reported in the primary trial publications; readers should look at those specific substudy reports rather than secondary summaries before using an exact number for individual expectations, since the headline weight-loss trial and the imaging substudy are not always the same publication.

Lifestyle factors: exercise, caloric restriction, and diet pattern

Sustained caloric deficit reduces visceral fat in both sexes, generally in proportion to total weight lost, though the exact ratio varies by study and population. Aerobic exercise without caloric restriction has been reported in some meta-analyses to produce a somewhat larger absolute VAT reduction in men than in premenopausal women, consistent with the idea that androgen-supported lipolytic activity in visceral fat differs by sex; after menopause this sex gap appears to narrow. Specific diet patterns, including Mediterranean-style diets, have shown visceral fat reduction beyond a standard low-fat diet in randomized trials, though mechanisms (polyphenol and microbiome-mediated effects have been proposed) remain an active area of research rather than settled fact.

Intermittent fasting protocols, including religious fasting patterns such as Ramadan, produce distinct patterns of change in markers of body fat storage compared with standard time-restricted eating, according to a 2024 comparative study (Ismail et al., 2024). That study evaluated markers of fat storage rather than DEXA-confirmed VAT specifically, so it should be read as evidence that fasting pattern matters for fat metabolism generally, not as direct proof of a VAT-specific effect independent of total caloric intake.

DEXA versus CT for measuring VAT

CT remains the imaging reference standard for visceral fat but exposes the patient to ionizing radiation, which limits its use for repeated monitoring. DEXA-derived VAT correlates reasonably well with CT in validation studies, though DEXA tends to introduce some systematic bias relative to CT, and different scanner manufacturers (Hologic, GE Lunar) use different proprietary algorithms. For anyone tracking VAT over time, the practical rule is to use the same machine and software version for every scan, since switching machines can produce an apparent change in VAT that reflects the equipment rather than the body.

A framework for interpreting a single VAT number

A VAT value on a DEXA report means different things depending on who is being scanned and why. Use this sequence before reacting to a number:

Step 1: Who is being scanned, and at what reproductive stage?

• Premenopausal woman: interpret the number against the expectation that VAT is naturally lower than in age-matched men; a value that looks "moderate" in absolute terms may represent a larger relative deviation from her own hormonal baseline and deserves attention sooner than the same number would in a man.
• Postmenopausal woman: interpret the number closer to male reference ranges, since the estrogen-mediated protection has diminished; do not assume the lower risk profile of premenopausal women still applies.
• Man: interpret against standard adult ranges, and consider checking testosterone if VAT is elevated and other hypogonadism symptoms are present, rather than assuming lifestyle is the only driver.

Step 2: Was the scan timed and equipment-matched for comparison?

• If comparing to a prior scan in a reproductive-age woman, check whether both scans were done at a similar cycle phase. If not, treat a small change (roughly under 10%) as possibly noise rather than a real trend.
• Confirm both scans used the same machine and software version. A change after switching equipment is not interpretable as a true biological change.

Step 3: Is the number isolated, or paired with metabolic markers?

• A VAT number without fasting insulin, triglycerides, HDL, and glucose tells an incomplete story. Two people with the same VAT can have very different metabolic risk depending on these markers.
• If VAT is elevated and metabolic markers are also abnormal, that combination is the trigger for clinical discussion, not the VAT number alone.

Step 4: What is the actual goal?

• If the goal is general cardiometabolic risk reduction: caloric deficit, aerobic exercise, and (in men with confirmed hypogonadism) testosterone therapy for hypogonadism, have trial evidence behind them for reducing VAT specifically.
• If the goal is major weight loss with obesity-related conditions: GLP-1 or dual GIP/GLP-1 agonist therapy is an FDA-approved option to discuss with a clinician, with visceral fat reduction as an observed but secondary imaging finding rather than the labeled indication.
• If considering hormone therapy (MHT or testosterone in women) specifically for body composition rather than symptom control: recognize this is not the primary approved use, and weigh it against the medication's established risks and benefits for its actual indication.

When to escalate to a clinician promptly, rather than just adjusting lifestyle: new or rapidly increasing abdominal girth with unexplained weight loss, signs of insulin resistance (such as new skin changes, unusual thirst, or blurred vision), or a VAT reading paired with abnormal fasting glucose or lipid panels. These combinations warrant medical evaluation rather than self-directed intervention.

Practical monitoring guidance

• Use the same DEXA machine and software version for all serial measurements.
• In premenopausal women, schedule scans at a consistent, ideally early-follicular, cycle phase.
• Recheck VAT roughly every 6-12 months during active intervention; more frequent scans are unlikely to show a real signal above measurement noise.
• Pair VAT with fasting insulin, glucose, triglycerides, and HDL for a fuller metabolic risk picture rather than relying on VAT in isolation.
• Treat any single scan's VAT number as one data point; trends over multiple consistently-timed scans are more informative than one reading.

References

• Ismail M, et al. Distinct biophysiological effects of Ramadan fasting and traditional intermittent fasting on markers of body fat storage: a real-life study (2024). https://pubmed.ncbi.nlm.nih.gov/39191620/

Other claims in this article draw on the broader published literature on visceral fat, sex hormones, menopause, and GLP-1/GIP receptor agonist trials. Specific numeric findings attributed to individual studies (exact percentage reductions, hazard ratios, and trial sample sizes) require verification against the primary trial publications before being used for individual clinical decisions or cited as precise figures.